{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:25:42Z","timestamp":1783661142745,"version":"3.55.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000069","name":"national institute of arthritis and musculoskeletal and skin diseases","doi-asserted-by":"publisher","award":["K24-AR063120 and R01- AR-070470"],"award-info":[{"award-number":["K24-AR063120 and R01- AR-070470"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"national institute of arthritis and musculoskeletal and skin diseases","doi-asserted-by":"publisher","award":["T32-AR007080"],"award-info":[{"award-number":["T32-AR007080"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"national institute of arthritis and musculoskeletal and skin diseases","doi-asserted-by":"publisher","award":["NIH\/NIAMS P50 AR060780"],"award-info":[{"award-number":["NIH\/NIAMS P50 AR060780"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"university hospitals hugo h\u00f4pitaux universitaires du grand ouest","award":["AAP JCM2020"],"award-info":[{"award-number":["AAP JCM2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-021-08891-0","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:02:50Z","timestamp":1630508570000},"page":"239-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8558","authenticated-orcid":false,"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roofeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lafyatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"8891_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. The Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"The Lancet"},{"key":"8891_CR2","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O et al (2015) Systemic sclerosis. Nat Rev Dis Primers 1:15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2","journal-title":"Nat Rev Dis Primers"},{"key":"8891_CR3","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/acr.23413","volume":"70","author":"A Lescoat","year":"2018","unstructured":"Lescoat A, Coiffier G, de Carlan M et al (2018) Combination of capillaroscopic and ultrasonographic evaluations in systemic sclerosis: results of a cross-sectional study. Arthritis Care Res (Hoboken) 70:938\u2013943. https:\/\/doi.org\/10.1002\/acr.23413","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8891_CR4","doi-asserted-by":"publisher","unstructured":"Denton CP, Lapadula G, Mouthon L, M\u00fcller-Ladner U (2009) Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 48(Suppl 3):iii32\u2013iii35. https:\/\/doi.org\/10.1093\/rheumatology\/ken483","DOI":"10.1093\/rheumatology\/ken483"},{"key":"8891_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","volume":"72","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova SI, Sari A, Harvey JC et al (2020) Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol 72:465\u2013476. https:\/\/doi.org\/10.1002\/art.41153","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR6","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2665-9913(19)30038-4","volume":"1","author":"A Lescoat","year":"2019","unstructured":"Lescoat A, Cavalin C, Ehrlich R et al (2019) The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. The Lancet Rheumatology 1:e257\u2013e264. https:\/\/doi.org\/10.1016\/S2665-9913(19)30038-4","journal-title":"The Lancet Rheumatology"},{"key":"8891_CR7","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"8891_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","volume":"46","author":"C Frantz","year":"2016","unstructured":"Frantz C, Avouac J, Distler O et al (2016) Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum 46:115\u2013123. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.02.005","journal-title":"Semin Arthritis Rheum"},{"key":"8891_CR9","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/rheumatology\/key214","volume":"57","author":"A Lescoat","year":"2018","unstructured":"Lescoat A, Ballerie A, Belhomme N et al (2018) Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study. Rheumatology (Oxford) 57:2012\u20132021. https:\/\/doi.org\/10.1093\/rheumatology\/key214","journal-title":"Rheumatology (Oxford)"},{"key":"8891_CR10","first-page":"96","volume":"31","author":"IAFM Heijnen","year":"2013","unstructured":"Heijnen IAFM, Foocharoen C, Bannert B et al (2013) Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol 31:96\u2013102","journal-title":"Clin Exp Rheumatol"},{"key":"8891_CR11","doi-asserted-by":"publisher","unstructured":"Clark KEN, Campochiaro C, Csomor E et al (2021) Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Ann Rheum Dis annrheumdis-2021\u2013220402. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220402","DOI":"10.1136\/annrheumdis-2021-220402"},{"key":"8891_CR12","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus Placebo in Scleroderma lung disease. N Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"8891_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"8891_CR14","doi-asserted-by":"publisher","unstructured":"Roofeh D, Lescoat A, Khanna D (2020) Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. Expert Opin Emerg Drugs 1\u201312. https:\/\/doi.org\/10.1080\/14728214.2020.1836156","DOI":"10.1080\/14728214.2020.1836156"},{"key":"8891_CR15","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30010-2","volume":"2","author":"JE Pope","year":"2020","unstructured":"Pope JE (2020) The future of treatment in systemic sclerosis: can we design better trials? Lancet Rheumatol 2:e185\u2013e194. https:\/\/doi.org\/10.1016\/S2665-9913(20)30010-2","journal-title":"Lancet Rheumatol"},{"key":"8891_CR16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 Classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative: ACR\/EULAR classification criteria for SSc. Arthritis Rheum 65:2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098","journal-title":"Arthritis Rheum"},{"key":"8891_CR17","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380:2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"8891_CR18","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630\u20132640. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"8891_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8:963\u2013974. https:\/\/doi.org\/10.1016\/S2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"key":"8891_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/BOR.0000000000000795","volume":"33","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lescoat A, Khanna D (2021) Treatment for systemic sclerosis-associated interstitial lung disease. Curr Opin Rheumatol 33:240\u2013248. https:\/\/doi.org\/10.1097\/BOR.0000000000000795","journal-title":"Curr Opin Rheumatol"},{"key":"8891_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2397198320902551","volume":"5","author":"M Kuwana","year":"2020","unstructured":"Kuwana M, Distler O (2020) Recent progress and missing gaps to achieve goal in the care of systemic sclerosis\u2013associated interstitial lung disease. J Scleroderma Relat Disord 5:3\u20135. https:\/\/doi.org\/10.1177\/2397198320902551","journal-title":"J Scleroderma Relat Disord"},{"key":"8891_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/art.41933","author":"D Khanna","year":"2021","unstructured":"Khanna D, Lescoat A, Roofeh D et al (2021) Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41933","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/annrheumdis-2011-200713","volume":"71","author":"M Kuwana","year":"2012","unstructured":"Kuwana M, Okazaki Y (2012) Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann Rheum Dis 71:617\u2013620. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200713","journal-title":"Ann Rheum Dis"},{"key":"8891_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.38953","volume":"67","author":"Y Shirai","year":"2015","unstructured":"Shirai Y, Okazaki Y, Inoue Y et al (2015) Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol 67:498\u2013507. https:\/\/doi.org\/10.1002\/art.38953","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214333","volume":"78","author":"A Lescoat","year":"2019","unstructured":"Lescoat A, Ballerie A, Jouneau S et al (2019) M1\/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis. Ann Rheum Dis 78:e127. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214333","journal-title":"Ann Rheum Dis"},{"key":"8891_CR26","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s10067-017-3597-6","volume":"36","author":"A Lescoat","year":"2017","unstructured":"Lescoat A, Lecureur V, Roussel M et al (2017) CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol 36:1649\u20131654. https:\/\/doi.org\/10.1007\/s10067-017-3597-6","journal-title":"Clin Rheumatol"},{"key":"8891_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-018-1694-9","volume":"20","author":"G Boleto","year":"2018","unstructured":"Boleto G, Guignabert C, Pezet S et al (2018) T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther 20:197. https:\/\/doi.org\/10.1186\/s13075-018-1694-9","journal-title":"Arthritis Res Ther"},{"key":"8891_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557\u2013567. https:\/\/doi.org\/10.1172\/JCI31139","journal-title":"J Clin Invest"},{"key":"8891_CR29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","volume":"10","author":"R Lafyatis","year":"2014","unstructured":"Lafyatis R (2014) Transforming growth factor \u03b2\u2013at the centre of systemic sclerosis. Nat Rev Rheumatol 10:706\u2013719. https:\/\/doi.org\/10.1038\/nrrheum.2014.137","journal-title":"Nat Rev Rheumatol"},{"key":"8891_CR30","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1172\/JCI131700","volume":"130","author":"T Maehara","year":"2020","unstructured":"Maehara T, Kaneko N, Perugino CA et al (2020) Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest 130:2451\u20132464. https:\/\/doi.org\/10.1172\/JCI131700","journal-title":"J Clin Invest"},{"key":"8891_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/art.40799","volume":"71","author":"A Lescoat","year":"2019","unstructured":"Lescoat A, Yelnik CM, Coiffier G et al (2019) Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross-sectional study. Arthritis Rheumatol (Hoboken, NJ) 71:983\u2013990. https:\/\/doi.org\/10.1002\/art.40799","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"8891_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00002281-200311000-00016","volume":"15","author":"ML Harris","year":"2003","unstructured":"Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778\u2013784. https:\/\/doi.org\/10.1097\/00002281-200311000-00016","journal-title":"Curr Opin Rheumatol"},{"key":"8891_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","volume":"22","author":"E Raschi","year":"2020","unstructured":"Raschi E, Privitera D, Bodio C et al (2020) Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Res Ther 22:265. https:\/\/doi.org\/10.1186\/s13075-020-02360-3","journal-title":"Arthritis Res Ther"},{"key":"8891_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-018-1689-6","volume":"20","author":"E Raschi","year":"2018","unstructured":"Raschi E, Chighizola CB, Cesana L et al (2018) Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Res Ther 20:187. https:\/\/doi.org\/10.1186\/s13075-018-1689-6","journal-title":"Arthritis Res Ther"},{"key":"8891_CR35","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP, Ong VH, Xu S et al (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 77:1362\u20131371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213031","journal-title":"Ann Rheum Dis"},{"key":"8891_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/art.40390","volume":"70","author":"TE Taher","year":"2018","unstructured":"Taher TE, Ong VH, Bystrom J et al (2018) Association of defective regulation of autoreactive interleukin-6-producing transitional B lymphocytes with disease in patients with systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ) 70:450\u2013461. https:\/\/doi.org\/10.1002\/art.40390","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"8891_CR37","doi-asserted-by":"publisher","first-page":"17300","DOI":"10.1038\/s41598-020-74179-6","volume":"10","author":"P Juhl","year":"2020","unstructured":"Juhl P, Bondesen S, Hawkins CL et al (2020) Dermal fibroblasts have different extracellular matrix profiles induced by TGF-\u03b2, PDGF and IL-6 in a model for skin fibrosis. Sci Rep 10:17300. https:\/\/doi.org\/10.1038\/s41598-020-74179-6","journal-title":"Sci Rep"},{"key":"8891_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug B, Khanna D, Swindell WR et al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79:379\u2013386. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215894","journal-title":"Ann Rheum Dis"},{"key":"8891_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.12.018","volume":"132","author":"B Skaug","year":"2020","unstructured":"Skaug B, Assassi S (2020) Type I interferon dysregulation in systemic sclerosis. Cytokine 132:154635. https:\/\/doi.org\/10.1016\/j.cyto.2018.12.018","journal-title":"Cytokine"},{"key":"8891_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/art.41627","author":"S Assassi","year":"2020","unstructured":"Assassi S, Li N, Volkmann ER et al (2020) Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41627","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR41","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/imcb.12217","volume":"97","author":"A Ballerie","year":"2019","unstructured":"Ballerie A, Lescoat A, Augagneur Y et al (2019) Efferocytosis capacities of blood monocyte-derived macrophages in systemic sclerosis. Immunol Cell Biol 97:340\u2013347. https:\/\/doi.org\/10.1111\/imcb.12217","journal-title":"Immunol Cell Biol"},{"key":"8891_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fimmu.2020.00219","volume":"11","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Ballerie A, Lelong M et al (2020) Crystalline silica impairs efferocytosis abilities of human and mouse macrophages: implication for silica-associated systemic sclerosis. Front Immunol 11:219. https:\/\/doi.org\/10.3389\/fimmu.2020.00219","journal-title":"Front Immunol"},{"key":"8891_CR43","doi-asserted-by":"publisher","unstructured":"Bhandari R, Ball MS, Martyanov V et al (2020) Pro-fibrotic activation of human macrophages in systemic sclerosis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41243","DOI":"10.1002\/art.41243"},{"key":"8891_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","volume":"72","author":"N Bellamri","year":"2019","unstructured":"Bellamri N, Morzadec C, Joannes A et al (2019) Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. Int Immunopharmacol 72:112\u2013123. https:\/\/doi.org\/10.1016\/j.intimp.2019.03.061","journal-title":"Int Immunopharmacol"},{"key":"8891_CR45","doi-asserted-by":"publisher","unstructured":"Tabib T, Huang M, Morse N et al (2021) Myofibroblast transcriptome indicates SFRP2+ fibroblast progenitors in systemic sclerosis skin. bioRxiv 2021.04.30.442148. https:\/\/doi.org\/10.1101\/2021.04.30.442148","DOI":"10.1101\/2021.04.30.442148"},{"key":"8891_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","volume":"16","author":"B Hinz","year":"2020","unstructured":"Hinz B, Lagares D (2020) Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol 16:11\u201331. https:\/\/doi.org\/10.1038\/s41584-019-0324-5","journal-title":"Nat Rev Rheumatol"},{"key":"8891_CR47","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1038\/ncomms11703","volume":"7","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya S, Wang W, Morales-Nebreda L et al (2016) Tenascin-C drives persistence of organ fibrosis. Nat Commun 7:11703. https:\/\/doi.org\/10.1038\/ncomms11703","journal-title":"Nat Commun"},{"key":"8891_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1172\/JCI66700","volume":"123","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Huang X, Hecker L et al (2013) Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 123:1096\u20131108. https:\/\/doi.org\/10.1172\/JCI66700","journal-title":"J Clin Invest"},{"key":"8891_CR49","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/art.33482","volume":"64","author":"D Lagares","year":"2012","unstructured":"Lagares D, Busnadiego O, Garc\u00eda-Fern\u00e1ndez RA et al (2012) Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum 64:1653\u20131664. https:\/\/doi.org\/10.1002\/art.33482","journal-title":"Arthritis Rheum"},{"key":"8891_CR50","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty D, \u0160umov\u00e1 B, Mallano T et al (2017) Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 8:1130. https:\/\/doi.org\/10.1038\/s41467-017-01236-6","journal-title":"Nat Commun"},{"key":"8891_CR51","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1923693","author":"A Lescoat","year":"2021","unstructured":"Lescoat A, Varga J, Matucci-Cerinic M, Khanna D (2021) New promising drugs for the treatment of systemic sclerosis: Pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs. https:\/\/doi.org\/10.1080\/13543784.2021.1923693","journal-title":"Expert Opin Investig Drugs"},{"key":"8891_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/BOR.0000000000000711","volume":"32","author":"D Roofeh","year":"2020","unstructured":"Roofeh D, Khanna D (2020) Management of systemic sclerosis: the first five years. Curr Opin Rheumatol 32:228\u2013237. https:\/\/doi.org\/10.1097\/BOR.0000000000000711","journal-title":"Curr Opin Rheumatol"},{"key":"8891_CR53","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, Meune C, Boubaya M et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 76:1897\u20131905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448","journal-title":"Ann Rheum Dis"},{"key":"8891_CR54","doi-asserted-by":"publisher","unstructured":"Bernstein EJ, Jaafar S, Assassi S et al (2020) Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ). https:\/\/doi.org\/10.1002\/art.41415","DOI":"10.1002\/art.41415"},{"key":"8891_CR55","doi-asserted-by":"publisher","unstructured":"Distler O, Assassi S, Cottin V et al (2020) Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 55. https:\/\/doi.org\/10.1183\/13993003.02026-2019","DOI":"10.1183\/13993003.02026-2019"},{"key":"8891_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","volume":"20","author":"V Cottin","year":"2019","unstructured":"Cottin V, Brown KK (2019) Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 20:13. https:\/\/doi.org\/10.1186\/s12931-019-0980-7","journal-title":"Respir Res"},{"key":"8891_CR57","doi-asserted-by":"publisher","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE et al (2021) Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res 7. https:\/\/doi.org\/10.1183\/23120541.00235-2020","DOI":"10.1183\/23120541.00235-2020"},{"key":"8891_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/2397198320903208","volume":"5","author":"D Roofeh","year":"2020","unstructured":"Roofeh D, Distler O, Allanore Y et al (2020) Treatment of systemic sclerosis\u2013associated interstitial lung disease: lessons from clinical trials. J Scleroderma Relat Disord 5:61\u201371. https:\/\/doi.org\/10.1177\/2397198320903208","journal-title":"J Scleroderma Relat Disord"},{"key":"8891_CR59","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/ar4672","volume":"16","author":"L Desallais","year":"2014","unstructured":"Desallais L, Avouac J, Fr\u00e9chet M et al (2014) Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 16:R157. https:\/\/doi.org\/10.1186\/ar4672","journal-title":"Arthritis Res Ther"},{"key":"8891_CR60","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ni.2865","volume":"15","author":"J Mauer","year":"2014","unstructured":"Mauer J, Chaurasia B, Goldau J et al (2014) Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 15:423\u2013430. https:\/\/doi.org\/10.1038\/ni.2865","journal-title":"Nat Immunol"},{"key":"8891_CR61","doi-asserted-by":"publisher","unstructured":"Morse C, Tabib T, Sembrat J et al (2019) Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J 54. https:\/\/doi.org\/10.1183\/13993003.02441-2018","DOI":"10.1183\/13993003.02441-2018"},{"key":"8891_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100140","volume":"1","author":"X Gao","year":"2020","unstructured":"Gao X, Jia G, Guttman A et al (2020) Osteopontin links myeloid activation and disease progression in systemic sclerosis. Cell Rep Med 1:100140. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100140","journal-title":"Cell Rep Med"},{"key":"8891_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/art.41668","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lin CJF, Goldin J et al (2021) Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41668","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR64","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/S2665-9913(21)00111-9","volume":"3","author":"CP Denton","year":"2021","unstructured":"Denton CP, Khanna D (2021) Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. Lancet Rheumatol 3:e321\u2013e323. https:\/\/doi.org\/10.1016\/S2665-9913(21)00111-9","journal-title":"Lancet Rheumatol"},{"key":"8891_CR65","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381:1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"8891_CR66","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1093\/rheumatology\/keab273","volume":"60","author":"Y Suleman","year":"2021","unstructured":"Suleman Y, Clark KEN, Cole AR et al (2021) Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. Rheumatology (Oxford) 60:3945\u20133946. https:\/\/doi.org\/10.1093\/rheumatology\/keab273","journal-title":"Rheumatology (Oxford)"},{"key":"8891_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/2397198319889549","volume":"5","author":"ER Volkmann","year":"2020","unstructured":"Volkmann ER (2020) Natural history of systemic sclerosis\u2013related interstitial lung disease: how to identify a progressive fibrosing phenotype. J Scleroderma Relat Disord 5:31\u201340. https:\/\/doi.org\/10.1177\/2397198319889549","journal-title":"J Scleroderma Relat Disord"},{"key":"8891_CR68","doi-asserted-by":"publisher","unstructured":"Lescoat A, Ballerie A, Augagneur Y et al (2018) Distinct properties of human M-CSF and GM-CSF monocyte-derived macrophages to simulate pathological lung conditions in vitro: application to systemic and inflammatory disorders with pulmonary involvement. Int J Mol Sci 19. https:\/\/doi.org\/10.3390\/ijms19030894","DOI":"10.3390\/ijms19030894"},{"key":"8891_CR69","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.taap.2015.04.007","volume":"285","author":"M Jaguin","year":"2015","unstructured":"Jaguin M, Fardel O, Lecureur V (2015) AhR-dependent secretion of PDGF-BB by human classically activated macrophages exposed to DEP extracts stimulates lung fibroblast proliferation. Toxicol Appl Pharmacol 285:170\u2013178. https:\/\/doi.org\/10.1016\/j.taap.2015.04.007","journal-title":"Toxicol Appl Pharmacol"},{"key":"8891_CR70","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953\u20131962. https:\/\/doi.org\/10.1002\/art.37988","journal-title":"Arthritis Rheum"},{"key":"8891_CR71","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45:1434\u20131445. https:\/\/doi.org\/10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"8891_CR72","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","volume":"76","author":"J Huang","year":"2017","unstructured":"Huang J, Maier C, Zhang Y et al (2017) Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis 76:1941\u20131948. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210823","journal-title":"Ann Rheum Dis"},{"key":"8891_CR73","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079\u20131087. https:\/\/doi.org\/10.1056\/NEJMoa1103690","journal-title":"N Engl J Med"},{"key":"8891_CR74","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082. https:\/\/doi.org\/10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"key":"8891_CR75","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/acr2.11125","volume":"2","author":"ER Volkmann","year":"2020","unstructured":"Volkmann ER, Tashkin DP, LeClair H et al (2020) Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II. ACR Open Rheumatol 2:362\u2013370. https:\/\/doi.org\/10.1002\/acr2.11125","journal-title":"ACR Open Rheumatol"},{"key":"8891_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas R, Tashkin DP, Furst DE et al (2018) Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res (Hoboken) 70:439\u2013444. https:\/\/doi.org\/10.1002\/acr.23282","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8891_CR77","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","volume":"15","author":"JG Goldin","year":"2018","unstructured":"Goldin JG, Kim GHJ, Tseng C-H et al (2018) Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II. Ann Am Thorac Soc 15:1286\u20131295. https:\/\/doi.org\/10.1513\/AnnalsATS.201802-079OC","journal-title":"Ann Am Thorac Soc"},{"key":"8891_CR78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M et al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 9:96\u2013106. https:\/\/doi.org\/10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"},{"key":"8891_CR79","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1402582","journal-title":"N Engl J Med"},{"key":"8891_CR80","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41374-017-0014-3","volume":"98","author":"CL Hall","year":"2018","unstructured":"Hall CL, Wells AR, Leung KP (2018) Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro. Lab Invest 98:640\u2013655. https:\/\/doi.org\/10.1038\/s41374-017-0014-3","journal-title":"Lab Invest"},{"key":"8891_CR81","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rheumatol 43:1672\u20131679. https:\/\/doi.org\/10.3899\/jrheum.151322","journal-title":"J Rheumatol"},{"key":"8891_CR82","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","volume":"40","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sharma SK, Mishra D et al (2020) Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int 40:703\u2013710. https:\/\/doi.org\/10.1007\/s00296-020-04565-w","journal-title":"Rheumatol Int"},{"key":"8891_CR83","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M et al (2021) Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 9:476\u2013486. https:\/\/doi.org\/10.1016\/S2213-2600(20)30554-3","journal-title":"Lancet Respir Med"},{"key":"8891_CR84","doi-asserted-by":"publisher","unstructured":"Fretheim H, Halse A-K, Seip M et al (2020) Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology keaa026. https:\/\/doi.org\/10.1093\/rheumatology\/keaa026","DOI":"10.1093\/rheumatology\/keaa026"},{"key":"8891_CR85","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D, Allanore Y, Denton CP et al (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis 79:618\u2013625. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216823","journal-title":"Ann Rheum Dis"},{"key":"8891_CR86","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S et al (2020) Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol 72:125\u2013136. https:\/\/doi.org\/10.1002\/art.41055","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR87","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","volume":"79","author":"Y Allanore","year":"2020","unstructured":"Allanore Y, Wung P, Soubrane C et al (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 79:1600\u20131607. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218447","journal-title":"Ann Rheum Dis"},{"key":"8891_CR88","unstructured":"Khanna D, Denton C, Furst D et al (2020) A phase 2a randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous systemic sclerosis (NOVESA). Arthritis Rheumatol 72 (suppl 10)"},{"key":"8891_CR89","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/art.39501","volume":"68","author":"D Khanna","year":"2016","unstructured":"Khanna D, Berrocal VJ, Giannini EH et al (2016) The American College of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ) 68:299\u2013311. https:\/\/doi.org\/10.1002\/art.39501","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"8891_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219100","author":"D Khanna","year":"2020","unstructured":"Khanna D, Huang S, Lin CJF, Spino C (2020) New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American college of rheumatology composite response index in systemic sclerosis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219100","journal-title":"Ann Rheum Dis"},{"key":"8891_CR91","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328\u2013332","journal-title":"J Rheumatol"},{"key":"8891_CR92","doi-asserted-by":"publisher","unstructured":"Alim K, Bruy\u00e8re A, Lescoat A et al (2021) Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Expert Opin Drug Metab Toxicol 1\u201313. https:\/\/doi.org\/10.1080\/17425255.2021.1862084","DOI":"10.1080\/17425255.2021.1862084"},{"key":"8891_CR93","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cellimm.2013.01.010","volume":"281","author":"M Jaguin","year":"2013","unstructured":"Jaguin M, Houlbert N, Fardel O, Lecureur V (2013) Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol 281:51\u201361. https:\/\/doi.org\/10.1016\/j.cellimm.2013.01.010","journal-title":"Cell Immunol"},{"key":"8891_CR94","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14\u201320. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.008","journal-title":"Immunity"},{"key":"8891_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Lelong M, Jeljeli M et al (2020) Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 178:114103. https:\/\/doi.org\/10.1016\/j.bcp.2020.114103","journal-title":"Biochem Pharmacol"},{"key":"8891_CR96","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S2665-9913(20)30007-2","volume":"2","author":"FD Galdo","year":"2020","unstructured":"Galdo FD, Hartley C, Allanore Y (2020) Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. Lancet Rheumatol 2:e173\u2013e184. https:\/\/doi.org\/10.1016\/S2665-9913(20)30007-2","journal-title":"Lancet Rheumatol"},{"key":"8891_CR97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-020-02383-w","volume":"23","author":"DA Fox","year":"2021","unstructured":"Fox DA, Lundy SK, Whitfield ML et al (2021) Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. Arthritis Res Ther 23:10. https:\/\/doi.org\/10.1186\/s13075-020-02383-w","journal-title":"Arthritis Res Ther"},{"key":"8891_CR98","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","volume":"75","author":"M Ponsoye","year":"2016","unstructured":"Ponsoye M, Frantz C, Ruzehaji N et al (2016) Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis 75:2142\u20132149. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208213","journal-title":"Ann Rheum Dis"},{"key":"8891_CR99","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","volume":"50","author":"I Castellv\u00ed","year":"2020","unstructured":"Castellv\u00ed I, Elhai M, Bruni C et al (2020) Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience. Semin Arthritis Rheum 50:1489\u20131493. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.12.004","journal-title":"Semin Arthritis Rheum"},{"key":"8891_CR100","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","volume":"2","author":"L Chung","year":"2020","unstructured":"Chung L, Spino C, McLain R et al (2020) Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. The Lancet Rheumatology 2:e743\u2013e753. https:\/\/doi.org\/10.1016\/S2665-9913(20)30237-X","journal-title":"The Lancet Rheumatology"},{"key":"8891_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0669-3","volume":"17","author":"EF Chakravarty","year":"2015","unstructured":"Chakravarty EF, Martyanov V, Fiorentino D et al (2015) Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther 17:1\u201314. https:\/\/doi.org\/10.1186\/s13075-015-0669-3","journal-title":"Arthritis Res Ther"},{"key":"8891_CR102","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/jid.2013.130","volume":"133","author":"M Hinchcliff","year":"2013","unstructured":"Hinchcliff M, Huang C-C, Wood TA et al (2013) Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 133:1979\u20131989. https:\/\/doi.org\/10.1038\/jid.2013.130","journal-title":"J Invest Dermatol"},{"key":"8891_CR103","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/art.40898","volume":"71","author":"JM Franks","year":"2019","unstructured":"Franks JM, Martyanov V, Cai G et al (2019) A machine learning classifier for assigning individual patients with systemic sclerosis to intrinsic molecular subsets. Arthritis Rheumatol 71:1701\u20131710. https:\/\/doi.org\/10.1002\/art.40898","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR104","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/jid.2011.472","volume":"132","author":"SA Pendergrass","year":"2012","unstructured":"Pendergrass SA, Lemaire R, Francis IP et al (2012) Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 132:1363\u20131373. https:\/\/doi.org\/10.1038\/jid.2011.472","journal-title":"J Invest Dermatol"},{"key":"8891_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41584-019-0257-z","volume":"34","author":"M Hinchcliff","year":"2019","unstructured":"Hinchcliff M, Mahoney JM (2019) Towards a new classification of systemic sclerosis. Nat Rev Rheumatol 34:1\u20132. https:\/\/doi.org\/10.1038\/s41584-019-0257-z","journal-title":"Nat Rev Rheumatol"},{"key":"8891_CR106","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"J-P Stasch","year":"2011","unstructured":"Stasch J-P, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123:2263\u20132273. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.981738","journal-title":"Circulation"},{"key":"8891_CR107","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, Gali\u00e8 N, Grimminger F et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330\u2013340. https:\/\/doi.org\/10.1056\/NEJMoa1209655","journal-title":"N Engl J Med"},{"key":"8891_CR108","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","volume":"76","author":"M Humbert","year":"2017","unstructured":"Humbert M, Coghlan JG, Ghofrani H-A et al (2017) Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 76:422\u2013426. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209087","journal-title":"Ann Rheum Dis"},{"key":"8891_CR109","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","volume":"74","author":"C Dees","year":"2015","unstructured":"Dees C, Beyer C, Distler A et al (2015) Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis 74:1621\u20131625. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206809","journal-title":"Ann Rheum Dis"},{"key":"8891_CR110","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/annrheumdis-2017-212489","volume":"77","author":"AE Matei","year":"2018","unstructured":"Matei AE, Beyer C, Gy\u00f6rfi AH et al (2018) Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann Rheum Dis 77:459. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212489","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"8891_CR111","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","volume":"122","author":"P Sandner","year":"2017","unstructured":"Sandner P, Stasch JP (2017) Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir Med 122(Suppl 1):S1\u2013S9. https:\/\/doi.org\/10.1016\/j.rmed.2016.08.022","journal-title":"Respir Med"},{"key":"8891_CR112","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/annrheumdis-2020-eular.3671","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D, Pope J, Matucci-Cerinic M et al (2020) Op0249 Long-term extension results of Rise-Ssc, a randomized trial of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcssc). Ann Rheum Dis 79:156\u2013157. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3671","journal-title":"Ann Rheum Dis"},{"key":"8891_CR113","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2020-eular.3138","volume":"79","author":"O Distler","year":"2020","unstructured":"Distler O, Kramer F, H\u00f6fler J et al (2020) Fri0575 Biomarker analysis from the Rise-Ssc study of riociguat in early diffuse cutaneous systemic sclerosis (dcssc). Ann Rheum Dis 79:890\u2013891. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3138","journal-title":"Ann Rheum Dis"},{"key":"8891_CR114","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.24395","volume":"60","author":"A Akhmetshina","year":"2009","unstructured":"Akhmetshina A, Dees C, Busch N et al (2009) The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 60:1129\u20131136. https:\/\/doi.org\/10.1002\/art.24395","journal-title":"Arthritis Rheum"},{"key":"8891_CR115","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","volume":"48","author":"E Garcia-Gonzalez","year":"2009","unstructured":"Garcia-Gonzalez E, Selvi E, Balistreri E et al (2009) Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford) 48:1050\u20131056. https:\/\/doi.org\/10.1093\/rheumatology\/kep189","journal-title":"Rheumatology (Oxford)"},{"key":"8891_CR116","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","volume":"71","author":"EG Gonzalez","year":"2012","unstructured":"Gonzalez EG, Selvi E, Balistreri E et al (2012) Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis 71:1545\u20131551. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200314","journal-title":"Ann Rheum Dis"},{"key":"8891_CR117","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-016-0373-0","volume":"17","author":"M Lucattelli","year":"2016","unstructured":"Lucattelli M, Fineschi S, Selvi E et al (2016) Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung. Respir Res 17:49. https:\/\/doi.org\/10.1186\/s12931-016-0373-0","journal-title":"Respir Res"},{"key":"8891_CR118","doi-asserted-by":"publisher","unstructured":"Spiera R, Hummers L, Chung L et al (2020) Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ). https:\/\/doi.org\/10.1002\/art.41294","DOI":"10.1002\/art.41294"},{"key":"8891_CR119","doi-asserted-by":"publisher","unstructured":"Hinchcliff M (2020) Lenabasum for skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ). https:\/\/doi.org\/10.1002\/art.41302","DOI":"10.1002\/art.41302"},{"key":"8891_CR120","unstructured":"Inc CPH (2020) Corbus pharmaceuticals announces topline results from RESOLVE-1 phase 3 study of lenabasum for treatment of systemic sclerosis. In: GlobeNewswire News Room. https:\/\/www.globenewswire.com\/news-release\/2020\/09\/08\/2089940\/0\/en\/Corbus-Pharmaceuticals-Announces-Topline-Results-from-RESOLVE-1-Phase-3-Study-of-Lenabasum-for-Treatment-of-Systemic-Sclerosis.html. Accessed 6 May 2021"},{"key":"8891_CR121","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","volume":"75","author":"N Ruzehaji","year":"2016","unstructured":"Ruzehaji N, Frantz C, Ponsoye M et al (2016) Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 75:2175\u20132183. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208029","journal-title":"Ann Rheum Dis"},{"key":"8891_CR122","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/cells8070733","volume":"8","author":"M Bros","year":"2019","unstructured":"Bros M, Haas K, Moll L, Grabbe S (2019) RhoA as a key regulator of innate and adaptive immunity. Cells 8:733. https:\/\/doi.org\/10.3390\/cells8070733","journal-title":"Cells"},{"key":"8891_CR123","doi-asserted-by":"publisher","unstructured":"Oh RS, Haak AJ, Smith KMJ et al (2018) RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation. J Cell Sci 131. https:\/\/doi.org\/10.1242\/jcs.209932","DOI":"10.1242\/jcs.209932"},{"key":"8891_CR124","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbalip.2012.06.014","volume":"1831","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Natarajan V (2013) Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling. Biochim Biophys Acta 1831:86\u201392. https:\/\/doi.org\/10.1016\/j.bbalip.2012.06.014","journal-title":"Biochim Biophys Acta"},{"key":"8891_CR125","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1002\/art.39797","volume":"68","author":"FV Castelino","year":"2016","unstructured":"Castelino FV, Bain G, Pace VA et al (2016) An autotaxin\/lysophosphatidic acid\/interleukin-6 amplification loop drives scleroderma fibrosis. Arthritis Rheumatol 68:2964\u20132974. https:\/\/doi.org\/10.1002\/art.39797","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR126","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/art.40547","volume":"70","author":"Y Allanore","year":"2018","unstructured":"Allanore Y, Distler O, Jagerschmidt A et al (2018) Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study. Arthritis Rheumatol 70:1634\u20131643. https:\/\/doi.org\/10.1002\/art.40547","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR127","doi-asserted-by":"publisher","unstructured":"Jagasia M, Lazaryan A, Bachier CR et al (2021) ROCK2 Inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol JCO2002754. https:\/\/doi.org\/10.1200\/JCO.20.02754","DOI":"10.1200\/JCO.20.02754"},{"key":"8891_CR128","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L et al (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378:35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327","journal-title":"N Engl J Med"},{"key":"8891_CR129","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311:2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"JAMA"},{"key":"8891_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102662","volume":"19","author":"P Di Benedetto","year":"2020","unstructured":"Di Benedetto P, Ruscitti P, Cipriani P, Giacomelli R (2020) Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. Autoimmun Rev 19:102662. https:\/\/doi.org\/10.1016\/j.autrev.2020.102662","journal-title":"Autoimmun Rev"},{"key":"8891_CR131","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-016-8552-9","volume":"52","author":"ATJ Maria","year":"2017","unstructured":"Maria ATJ, Maumus M, Le Quellec A et al (2017) Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol 52:234\u2013259. https:\/\/doi.org\/10.1007\/s12016-016-8552-9","journal-title":"Clin Rev Allergy Immunol"},{"key":"8891_CR132","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3389\/fimmu.2018.02938","volume":"9","author":"P Rozier","year":"2018","unstructured":"Rozier P, Maria A, Goulabchand R et al (2018) Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use? Front Immunol 9:2938. https:\/\/doi.org\/10.3389\/fimmu.2018.02938","journal-title":"Front Immunol"},{"key":"8891_CR133","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/art.39477","volume":"68","author":"ATJ Maria","year":"2016","unstructured":"Maria ATJ, Toupet K, Bony C et al (2016) Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ) 68:1013\u20131025. https:\/\/doi.org\/10.1002\/art.39477","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"8891_CR134","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/annrheumdis-2018-214218","volume":"78","author":"J Magalon","year":"2019","unstructured":"Magalon J, Velier M, Simoncini S et al (2019) Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. Ann Rheum Dis 78:391\u2013398. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214218","journal-title":"Ann Rheum Dis"},{"key":"8891_CR135","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1136\/annrheumdis-2014-205681","volume":"74","author":"B Granel","year":"2015","unstructured":"Granel B, Daumas A, Jouve E et al (2015) Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis 74:2175\u20132182. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205681","journal-title":"Ann Rheum Dis"},{"key":"8891_CR136","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/rheumatology\/kev323","volume":"55","author":"P Guillaume-Jugnot","year":"2016","unstructured":"Guillaume-Jugnot P, Daumas A, Magalon J et al (2016) Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology (Oxford) 55:301\u2013306. https:\/\/doi.org\/10.1093\/rheumatology\/kev323","journal-title":"Rheumatology (Oxford)"},{"key":"8891_CR137","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees C, Tomcik M, Palumbo-Zerr K et al (2012) JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum 64:3006\u20133015. https:\/\/doi.org\/10.1002\/art.34500","journal-title":"Arthritis Rheum"},{"key":"8891_CR138","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1074\/jbc.M208544200","volume":"278","author":"VJ Thannickal","year":"2003","unstructured":"Thannickal VJ, Lee DY, White ES et al (2003) Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 278:12384\u201312389. https:\/\/doi.org\/10.1074\/jbc.M208544200","journal-title":"J Biol Chem"},{"key":"8891_CR139","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1073\/pnas.83.12.4167","volume":"83","author":"AB Roberts","year":"1986","unstructured":"Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 83:4167\u20134171","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8891_CR140","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1042\/bj2470597","volume":"247","author":"J Varga","year":"1987","unstructured":"Varga J, Rosenbloom J, Jimenez SA (1987) Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 247:597\u2013604. https:\/\/doi.org\/10.1042\/bj2470597","journal-title":"Biochem J"},{"key":"8891_CR141","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM, Padilla CM, McLaughlin SR et al (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125:2795\u20132807. https:\/\/doi.org\/10.1172\/JCI77958","journal-title":"J Clin Invest"},{"key":"8891_CR142","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","volume":"14","author":"B-G Kim","year":"2021","unstructured":"Kim B-G, Malek E, Choi SH et al (2021) Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol 14:55. https:\/\/doi.org\/10.1186\/s13045-021-01053-x","journal-title":"J Hematol Oncol"},{"key":"8891_CR143","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1136\/annrheumdis-2020-eular.1753","volume":"79","author":"R Lafyatis","year":"2020","unstructured":"Lafyatis R, Spiera R, Domsic R et al (2020) Thu0329 safety, target engagement, and initial efficacy of Avid200, a first-in-class potent and isoform-selective inhibitor of Tgf-beta 1 and 3, in patients with diffuse cutaneous systemic sclerosis (dcssc): a phase 1 dose escalation study. Ann Rheum Dis 79:394\u2013395. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.1753","journal-title":"Ann Rheum Dis"},{"key":"8891_CR144","doi-asserted-by":"publisher","unstructured":"Huynh LK, Hipolito CJ, Ten Dijke P (2019) A perspective on the development of TGF-\u03b2 inhibitors for cancer treatment. Biomolecules 9. https:\/\/doi.org\/10.3390\/biom9110743","DOI":"10.3390\/biom9110743"},{"key":"8891_CR145","doi-asserted-by":"crossref","unstructured":"Khanna D, Tashkin DP, Wells AU et al (2021) STRATUS: a phase II study of abituzumab in patients with systemic sclerosis\u2013associated interstitial lung disease. J Rheumatol. in press","DOI":"10.3899\/jrheum.191365"},{"key":"8891_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186740","volume":"12","author":"H Murphy-Marshman","year":"2017","unstructured":"Murphy-Marshman H, Quensel K, Shi-Wen X et al (2017) Antioxidants and NOX1\/NOX4 inhibition blocks TGF\u03b21-induced CCN2 and \u03b1-SMA expression in dermal and gingival fibroblasts. PLoS One 12:e0186740. https:\/\/doi.org\/10.1371\/journal.pone.0186740","journal-title":"PLoS One"},{"key":"8891_CR147","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.21725","volume":"54","author":"Y Chen","year":"2006","unstructured":"Chen Y, Shi-wen X, Eastwood M et al (2006) Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 54:1309\u20131316. https:\/\/doi.org\/10.1002\/art.21725","journal-title":"Arthritis Rheum"},{"key":"8891_CR148","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-020-03952-y","author":"Q Da","year":"2020","unstructured":"Da Q, Yan Z, Li Z et al (2020) TAK1 is involved in sodium L-lactate-stimulated p38 signaling and promotes apoptosis. Mol Cell Biochem. https:\/\/doi.org\/10.1007\/s11010-020-03952-y","journal-title":"Mol Cell Biochem"},{"key":"8891_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene 285:1\u201324. https:\/\/doi.org\/10.1016\/s0378-1119(02)00398-0","journal-title":"Gene"},{"key":"8891_CR150","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14876","volume":"32","author":"SC Deverapalli","year":"2018","unstructured":"Deverapalli SC, Rosmarin D (2018) The use of JAK inhibitors in the treatment of progressive systemic sclerosis. J Eur Acad Dermatol Venereol 32:e328. https:\/\/doi.org\/10.1111\/jdv.14876","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8891_CR151","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMoa1310476","journal-title":"N Engl J Med"},{"key":"8891_CR152","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243\u20131252. https:\/\/doi.org\/10.1056\/NEJMoa1507247","journal-title":"N Engl J Med"},{"key":"8891_CR153","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K et al (2020) Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156:1333\u20131343. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260","journal-title":"JAMA Dermatol"},{"key":"8891_CR154","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2397198319865367","volume":"5","author":"W Wang","year":"2020","unstructured":"Wang W, Bhattacharyya S, Marangoni RG et al (2020) The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord 5:40\u201350. https:\/\/doi.org\/10.1177\/2397198319865367","journal-title":"J Scleroderma Relat Disord"},{"key":"8891_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.12.007","author":"WW Aung","year":"2020","unstructured":"Aung WW, Wang C, Xibei J et al (2020) Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. J Dermatol Sci. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.12.007","journal-title":"J Dermatol Sci"},{"key":"8891_CR156","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/imt-2020-0270","volume":"13","author":"R Talotta","year":"2020","unstructured":"Talotta R (2020) The rationale for targeting the JAK\/STAT pathway in scleroderma-associated interstitial lung disease. Immunotherapy 13:241\u2013256. https:\/\/doi.org\/10.2217\/imt-2020-0270","journal-title":"Immunotherapy"},{"key":"8891_CR157","unstructured":"Khanna D, Nagaraja V, Koenig A et al (2019) Tofacitinib in early diffuse cutaneous systemic sclerosis\u2014 results of phase I\/II investigator-initiated, double-blind randomized placebo-controlled trial. ACR Meeting Abstracts"},{"key":"8891_CR158","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/imt-2017-0156","volume":"10","author":"M Jagasia","year":"2018","unstructured":"Jagasia M, Zeiser R, Arbushites M et al (2018) Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy 10:391\u2013402. https:\/\/doi.org\/10.2217\/imt-2017-0156","journal-title":"Immunotherapy"},{"key":"8891_CR159","doi-asserted-by":"crossref","unstructured":"Zeiser R (2020) Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory\/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study. ASH","DOI":"10.1182\/blood-2020-137694"},{"key":"8891_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00041-2","volume":"3","author":"TL Rheumatology","year":"2021","unstructured":"Rheumatology TL (2021) JAK inhibitors: fate in doubt for rheumatoid arthritis? Lancet Rheumatol 3:e161. https:\/\/doi.org\/10.1016\/S2665-9913(21)00041-2","journal-title":"Lancet Rheumatol"},{"key":"8891_CR161","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"SS Baroni","year":"2006","unstructured":"Baroni SS, Santillo M, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667\u20132676. https:\/\/doi.org\/10.1056\/NEJMoa052955","journal-title":"N Engl J Med"},{"key":"8891_CR162","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","volume":"190","author":"MO Becker","year":"2014","unstructured":"Becker MO, Kill A, Kutsche M et al (2014) Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190:808\u2013817. https:\/\/doi.org\/10.1164\/rccm.201403-0442OC","journal-title":"Am J Respir Crit Care Med"},{"key":"8891_CR163","doi-asserted-by":"publisher","unstructured":"Matsushita T, Kobayashi T, Mizumaki K et al (2018) BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv 4:eaas9944. https:\/\/doi.org\/10.1126\/sciadv.aas9944","DOI":"10.1126\/sciadv.aas9944"},{"key":"8891_CR164","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","volume":"169","author":"M Hasegawa","year":"2006","unstructured":"Hasegawa M, Hamaguchi Y, Yanaba K et al (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954\u2013966. https:\/\/doi.org\/10.2353\/ajpath.2006.060205","journal-title":"Am J Pathol"},{"key":"8891_CR165","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O et al (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78:979\u2013987. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214816","journal-title":"Ann Rheum Dis"},{"key":"8891_CR166","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa550","author":"RP Goswami","year":"2020","unstructured":"Goswami RP, Ray A, Chatterjee M et al (2020) Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaa550","journal-title":"Rheumatology (Oxford)"},{"key":"8891_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R Tang","year":"2020","unstructured":"Tang R, Yu J, Shi Y et al (2020) Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis. Int Immunopharmacol 83:106389. https:\/\/doi.org\/10.1016\/j.intimp.2020.106389","journal-title":"Int Immunopharmacol"},{"key":"8891_CR168","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3481OC","author":"RT Zamanian","year":"2021","unstructured":"Zamanian RT, Badesch D, Chung L et al (2021) Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis associated pulmonary arterial hypertension: a multi-center, double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. https:\/\/doi.org\/10.1164\/rccm.202009-3481OC","journal-title":"Am J Respir Crit Care Med"},{"key":"8891_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(21)00107-7","journal-title":"Lancet Rheumatol"},{"key":"8891_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00149-1","author":"M Hughes","year":"2021","unstructured":"Hughes M, Khanna D (2021) Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(21)00149-1","journal-title":"Lancet Rheumatol"},{"key":"8891_CR171","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM et al (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 70:308\u2013316. https:\/\/doi.org\/10.1002\/art.40358","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR172","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13075-020-02153-8","volume":"22","author":"J Einhaus","year":"2020","unstructured":"Einhaus J, Pecher A-C, Asteriti E et al (2020) Inhibition of effector B cells by ibrutinib in systemic sclerosis. Arthritis Res Ther 22:66. https:\/\/doi.org\/10.1186\/s13075-020-02153-8","journal-title":"Arthritis Res Ther"},{"key":"8891_CR173","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","volume":"25","author":"EK Waller","year":"2019","unstructured":"Waller EK, Miklos D, Cutler C et al (2019) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study. Biol Blood Marrow Transplant 25:2002\u20132007. https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.023","journal-title":"Biol Blood Marrow Transplant"},{"key":"8891_CR174","doi-asserted-by":"publisher","unstructured":"Dinparastisaleh R, Mirsaeidi M (2021) Antifibrotic and anti-inflammatory actions of \u03b1-melanocytic hormone: new roles for an old player. Pharmaceuticals (Basel) 14. https:\/\/doi.org\/10.3390\/ph14010045","DOI":"10.3390\/ph14010045"},{"key":"8891_CR175","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3389\/fphar.2018.01535","volume":"9","author":"C Spana","year":"2018","unstructured":"Spana C, Taylor AW, Yee DG et al (2018) Probing the role of melanocortin type 1 receptor agonists in diverse immunological diseases. Front Pharmacol 9:1535. https:\/\/doi.org\/10.3389\/fphar.2018.01535","journal-title":"Front Pharmacol"},{"key":"8891_CR176","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/art.24228","volume":"60","author":"A Kokot","year":"2009","unstructured":"Kokot A, Sindrilaru A, Schiller M et al (2009) alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum 60:592\u2013603. https:\/\/doi.org\/10.1002\/art.24228","journal-title":"Arthritis Rheum"},{"key":"8891_CR177","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2018.07.033","volume":"80","author":"V Leroy","year":"2019","unstructured":"Leroy V, Henrot P, Barnetche T et al (2019) Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: analysis of a cohort of 239 patients. J Am Acad Dermatol 80:478\u2013484. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.033","journal-title":"J Am Acad Dermatol"},{"key":"8891_CR178","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/01.shk.0000239764.80033.7e","volume":"27","author":"G Colombo","year":"2007","unstructured":"Colombo G, Gatti S, Sordi A et al (2007) Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury. Shock 27:326\u2013333. https:\/\/doi.org\/10.1097\/01.shk.0000239764.80033.7e","journal-title":"Shock"},{"key":"8891_CR179","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1084\/jem.185.12.2171","volume":"185","author":"U Forssmann","year":"1997","unstructured":"Forssmann U, Uguccioni M, Loetscher P et al (1997) Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 185:2171\u20132176. https:\/\/doi.org\/10.1084\/jem.185.12.2171","journal-title":"J Exp Med"},{"key":"8891_CR180","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13069-015-0028-7","volume":"8","author":"R Lee","year":"2015","unstructured":"Lee R, Reese C, Perry B et al (2015) Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1. Fibrogenesis Tissue Repair 8:11. https:\/\/doi.org\/10.1186\/s13069-015-0028-7","journal-title":"Fibrogenesis Tissue Repair"},{"key":"8891_CR181","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1136\/annrheumdis-2019-215119","volume":"78","author":"A Mor","year":"2019","unstructured":"Mor A, Salto MS, Katav A et al (2019) Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Ann Rheum Dis 78:1260\u20131268. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215119","journal-title":"Ann Rheum Dis"},{"key":"8891_CR182","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/jcp.25946","volume":"232","author":"JK Buskermolen","year":"2017","unstructured":"Buskermolen JK, Roffel S, Gibbs S (2017) Stimulation of oral fibroblast chemokine receptors identifies CCR3 and CCR4 as potential wound healing targets. J Cell Physiol 232:2996\u20133005. https:\/\/doi.org\/10.1002\/jcp.25946","journal-title":"J Cell Physiol"},{"key":"8891_CR183","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/pr501149m","volume":"14","author":"MW Foster","year":"2015","unstructured":"Foster MW, Morrison LD, Todd JL et al (2015) Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. J Proteome Res 14:1238\u20131249. https:\/\/doi.org\/10.1021\/pr501149m","journal-title":"J Proteome Res"},{"key":"8891_CR184","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4049\/jimmunol.1701093","volume":"201","author":"\u00c1 Dom\u00ednguez-Soto","year":"2018","unstructured":"Dom\u00ednguez-Soto \u00c1, Sim\u00f3n-Fuentes M, de Las C-E et al (2018) IVIg promote cross-tolerance against inflammatory stimuli in vitro and in vivo. J Immunol 201:41\u201352. https:\/\/doi.org\/10.4049\/jimmunol.1701093","journal-title":"J Immunol"},{"key":"8891_CR185","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176\u2013189. https:\/\/doi.org\/10.1038\/nri3401","journal-title":"Nat Rev Immunol"},{"key":"8891_CR186","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","volume":"98","author":"LK Kozicky","year":"2015","unstructured":"Kozicky LK, Zhao ZY, Menzies SC et al (2015) Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. J Leukoc Biol 98:983\u2013994. https:\/\/doi.org\/10.1189\/jlb.3VMA0315-078R","journal-title":"J Leukoc Biol"},{"key":"8891_CR187","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","volume":"44","author":"Y Asano","year":"2005","unstructured":"Asano Y, Ihn H, Asashima N et al (2005) A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford) 44:824\u2013826. https:\/\/doi.org\/10.1093\/rheumatology\/keh600","journal-title":"Rheumatology (Oxford)"},{"key":"8891_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102431","volume":"19","author":"B Chaigne","year":"2020","unstructured":"Chaigne B, Rodeia S, Benmostefa N et al (2020) Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients. Autoimmun Rev 19:102431. https:\/\/doi.org\/10.1016\/j.autrev.2019.102431","journal-title":"Autoimmun Rev"},{"key":"8891_CR189","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","volume":"16","author":"S Sanges","year":"2017","unstructured":"Sanges S, Rivi\u00e8re S, Mekinian A et al (2017) Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 16:377\u2013384. https:\/\/doi.org\/10.1016\/j.autrev.2017.02.008","journal-title":"Autoimmun Rev"},{"key":"8891_CR190","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S (2013) A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 31:151\u2013156","journal-title":"Clin Exp Rheumatol"},{"key":"8891_CR191","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrrheum.2014.128","volume":"10","author":"JCA Broen","year":"2014","unstructured":"Broen JCA, Radstake TRDJ, Rossato M (2014) The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 10:671\u2013681. https:\/\/doi.org\/10.1038\/nrrheum.2014.128","journal-title":"Nat Rev Rheumatol"},{"key":"8891_CR192","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-019-0896-x","volume":"566","author":"T Wohlfahrt","year":"2019","unstructured":"Wohlfahrt T, Rauber S, Uebe S et al (2019) PU.1 controls fibroblast polarization and tissue fibrosis. Nature 566:344\u2013349. https:\/\/doi.org\/10.1038\/s41586-019-0896-x","journal-title":"Nature"},{"key":"8891_CR193","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.40934","volume":"71","author":"V Martyanov","year":"2019","unstructured":"Martyanov V, Whitfield ML, Varga J (2019) Senescence signature in skin biopsies from systemic sclerosis patients treated with senolytic therapy: potential predictor of clinical response? Arthritis Rheumatol 71:1766\u20131767. https:\/\/doi.org\/10.1002\/art.40934","journal-title":"Arthritis Rheumatol"},{"key":"8891_CR194","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41590-020-0646-0","volume":"21","author":"RPH De Maeyer","year":"2020","unstructured":"De Maeyer RPH, van de Merwe RC, Louie R et al (2020) Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. Nat Immunol 21:615\u2013625. https:\/\/doi.org\/10.1038\/s41590-020-0646-0","journal-title":"Nat Immunol"},{"key":"8891_CR195","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","volume":"15","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER, Varga J (2019) Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol 15:208\u2013224. https:\/\/doi.org\/10.1038\/s41584-019-0184-z","journal-title":"Nat Rev Rheumatol"},{"key":"8891_CR196","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00408-018-0134-6","volume":"196","author":"R Kanemaru","year":"2018","unstructured":"Kanemaru R, Takahashi F, Kato M et al (2018) Dasatinib suppresses TGF\u03b2-mediated epithelial-mesenchymal transition in alveolar epithelial cells and inhibits pulmonary fibrosis. Lung 196:531\u2013541. https:\/\/doi.org\/10.1007\/s00408-018-0134-6","journal-title":"Lung"},{"key":"8891_CR197","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","volume":"9","author":"C Frantz","year":"2018","unstructured":"Frantz C, Auffray C, Avouac J, Allanore Y (2018) Regulatory T cells in systemic sclerosis. Front Immunol 9:2356. https:\/\/doi.org\/10.3389\/fimmu.2018.02356","journal-title":"Front Immunol"},{"key":"8891_CR198","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P et al (2019) Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 78:209\u2013217. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214229","journal-title":"Ann Rheum Dis"},{"key":"8891_CR199","doi-asserted-by":"publisher","unstructured":"Barbieri A, Dolcino M, Tinazzi E et al (2015) Characterization of CD30\/CD30L+ cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis. J Immunol Res 2015. https:\/\/doi.org\/10.1155\/2015\/729654","DOI":"10.1155\/2015\/729654"},{"key":"8891_CR200","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cei.13477","volume":"201","author":"K Higashioka","year":"2020","unstructured":"Higashioka K, Kikushige Y, Ayano M et al (2020) Generation of a novel CD30+ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis. Clin Exp Immunol 201:233\u2013243. https:\/\/doi.org\/10.1111\/cei.13477","journal-title":"Clin Exp Immunol"},{"key":"8891_CR201","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-020-00561-w","volume":"15","author":"L Shea","year":"2020","unstructured":"Shea L, Mehta-Shah N (2020) Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma. Curr Hematol Malig Rep 15:9\u201319. https:\/\/doi.org\/10.1007\/s11899-020-00561-w","journal-title":"Curr Hematol Malig Rep"},{"key":"8891_CR202","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-017-1356-3","volume":"19","author":"K Makino","year":"2017","unstructured":"Makino K, Makino T, Stawski L et al (2017) Anti-connective tissue growth factor (CTGF\/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res Ther 19:134. https:\/\/doi.org\/10.1186\/s13075-017-1356-3","journal-title":"Arthritis Res Ther"},{"key":"8891_CR203","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/jid.2015.188","volume":"135","author":"X Guo","year":"2015","unstructured":"Guo X, Higgs BW, Bay-Jensen AC et al (2015) Suppression of T cell activation and collagen accumulation by an Anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol 135:2402\u20132409. https:\/\/doi.org\/10.1038\/jid.2015.188","journal-title":"J Invest Dermatol"},{"key":"8891_CR204","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"8891_CR205","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S2665-9913(20)30342-8","volume":"3","author":"IN Bruce","year":"2021","unstructured":"Bruce IN, Nami A, Schwetje E et al (2021) Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol 3:e101\u2013e110. https:\/\/doi.org\/10.1016\/S2665-9913(20)30342-8","journal-title":"Lancet Rheumatol"},{"key":"8891_CR206","doi-asserted-by":"publisher","unstructured":"Lescoat A, Murphy SL, Roofeh D et al (2020) Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. J Scleroderma Relat Disord 2397198320961967. https:\/\/doi.org\/10.1177\/2397198320961967","DOI":"10.1177\/2397198320961967"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08891-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T08:14:09Z","timestamp":1683706449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08891-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":206,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["8891"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08891-0","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"24 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"AL: Nothing to disclose. DR: Nothing to disclose. MK: Grant support from Boehringer-Ingelheim, Ono Pharmaceuticals, Consultant: AbbVie, Boehringer-Ingelheim, Corbus, Mochida, Kissei, Galapagos NV, Speaker bureau: Asahi Kasei Pharma, Astellas, Boehringer-Ingelheim, Chugai. GSK, Janssen. Mitsubishi-Tanabe, Nippon Shinyaku. RL: has served as a consultant for Pfizer, Bristol Myers Squibb, Boehringer-Ingleheim, Formation, Sanofi, Boehringer-Mannheim, Merck and Genentech\/Roche; holds or recently had research grants from Corbus, Formation, Moderna, Regeneron, Pfizer and Kiniksa and holds equity in Thirona Bio. YA: Grant support from Alpine ImmunoSciences, Roche and Sanofi. Consultant: Bayer, Boehringer Ingelheim, Genentech\/Roche, Medsenic, Sanofi-Aventis. DK: Grant support from NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer. Consultant: Acceleron, Actelion, Abbvie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Gilead, Galapagos, Genentech\/Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics. Stocks: Eicos Sciences, Inc (less than 5%). Leadership\/Equity position \u2013 Chief Medical Officer, CiviBioPharma\/Eicos Sciences, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}